Beta Bionics, Inc. BBNX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 127.27M | 119.01M | 110.24M | 100.25M | 88.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 127.27M | 119.01M | 110.24M | 100.25M | 88.57M |
| Cost of Revenue | 52.65M | 49.61M | 47.24M | 44.71M | 40.29M |
| Gross Profit | 74.61M | 69.40M | 63.00M | 55.54M | 48.28M |
| SG&A Expenses | 124.49M | 113.50M | 102.76M | 92.43M | 83.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 219.85M | 202.03M | 187.55M | 171.93M | 157.16M |
| Operating Income | -92.58M | -83.02M | -77.31M | -71.68M | -68.59M |
| Income Before Tax | -83.12M | -72.97M | -66.44M | -73.20M | -77.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -83.12 | -72.97 | -66.44 | -73.20 | -77.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.12M | -72.97M | -66.44M | -73.20M | -77.84M |
| EBIT | -92.58M | -83.02M | -77.31M | -71.68M | -68.59M |
| EBITDA | -89.86M | -80.80M | -75.46M | -70.11M | -67.33M |
| EPS Basic | -1.85 | -1.65 | -1.51 | -1.95 | -4.36 |
| Normalized Basic EPS | -1.15 | -1.03 | -0.94 | -1.22 | -2.73 |
| EPS Diluted | -1.85 | -1.65 | -1.51 | -1.95 | -4.36 |
| Normalized Diluted EPS | -1.15 | -1.03 | -0.94 | -1.22 | -2.73 |
| Average Basic Shares Outstanding | 179.72M | 176.81M | 175.66M | 161.93M | 124.41M |
| Average Diluted Shares Outstanding | 179.72M | 176.81M | 175.66M | 161.93M | 124.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |